Protein Signatures Reveal Heart Failure Subtypes Are Biologically Distinct in Diabetic Patients
Proteomic profiling of ~5,000 proteins across heart failure subtypes in the EXSCEL trial reveals distinct biological pathways, with exenatide modifying some protein signatures.
Quick Facts
What This Study Found
Profiling ~5,000 proteins revealed distinct biological pathways across HFpEF, HFmrEF, and HFrEF in diabetic patients, with exenatide modifying some proteomic signatures.
Key Numbers
1,199 participants with prevalent HF from EXSCEL trial. ~5,000 proteins profiled via SomaScan. Compared HFpEF (EF>55%), HFmrEF (40-55%), HFrEF (<40%). Baseline and 12-month samples.
How They Did This
Proteomic substudy of the EXSCEL randomized trial using SomaLogic SomaScan platform to measure ~5,000 proteins in baseline and 12-month samples from 1,199 participants with T2DM.
Why This Research Matters
Understanding the biological differences between heart failure subtypes could lead to subtype-specific treatments rather than one-size-fits-all approaches.
The Bigger Picture
This work supports precision medicine in heart failure — treating patients based on their specific disease biology rather than just ejection fraction numbers.
What This Study Doesn't Tell Us
Substudy of a trial not designed for heart failure as primary endpoint. Proteomic associations are observational and need functional validation.
Questions This Raises
- ?Can proteomic profiles guide heart failure treatment selection?
- ?Do other GLP-1 drugs produce similar proteomic changes to exenatide?
Trust & Context
- Key Stat:
- ~5,000 proteins analyzed Comprehensive proteomic profiling revealed distinct biological pathways across heart failure ejection fraction subtypes
- Evidence Grade:
- Post hoc proteomic analysis of a major RCT — strong methodology but exploratory in nature. Findings need prospective validation.
- Study Age:
- Published in 2025, using state-of-the-art proteomics to characterize heart failure biology in the EXSCEL trial.
- Original Title:
- Proteomic pathways across the ejection fraction spectrum in patients with heart failure and diabetes mellitus: an EXSCEL trial substudy.
- Published In:
- Scientific reports, 15(1), 30170 (2025)
- Authors:
- Peters, Anthony E, Nguyen, Maggie, Green, Jennifer B(4), Pearson, Ewan R, Buse, John B, Sourij, Harald, Hernandez, Adrian F, Sattar, Naveed, Holman, Rury R, Mentz, Robert J, Shah, Svati H
- Database ID:
- RPEP-13032
Evidence Hierarchy
Frequently Asked Questions
Are all types of heart failure the same?
No. This study proves that HFpEF, HFmrEF, and HFrEF have distinct protein signatures in the blood, meaning they are biologically different conditions — not just different degrees of the same disease.
Did the GLP-1 drug change heart failure biology?
Yes, exenatide modified some proteomic pathways at 12 months, suggesting GLP-1 drugs affect heart failure biology at the molecular level, not just through weight loss or blood sugar improvements.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-13032APA
Peters, Anthony E; Nguyen, Maggie; Green, Jennifer B; Pearson, Ewan R; Buse, John B; Sourij, Harald; Hernandez, Adrian F; Sattar, Naveed; Holman, Rury R; Mentz, Robert J; Shah, Svati H. (2025). Proteomic pathways across the ejection fraction spectrum in patients with heart failure and diabetes mellitus: an EXSCEL trial substudy.. Scientific reports, 15(1), 30170. https://doi.org/10.1038/s41598-025-14414-0
MLA
Peters, Anthony E, et al. "Proteomic pathways across the ejection fraction spectrum in patients with heart failure and diabetes mellitus: an EXSCEL trial substudy.." Scientific reports, 2025. https://doi.org/10.1038/s41598-025-14414-0
RethinkPeptides
RethinkPeptides Research Database. "Proteomic pathways across the ejection fraction spectrum in ..." RPEP-13032. Retrieved from https://rethinkpeptides.com/research/peters-2025-proteomic-pathways-across-the
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.